Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(2):255–259. doi: 10.1038/bjc.1996.45

Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden.

C Wassberg 1, M Thörn 1, J Yuen 1, U Ringborg 1, T Hakulinen 1
PMCID: PMC2074325  PMID: 8546916

Abstract

To quantify the risk of second primary cancers among patients with cutaneous malignant melanoma, we studied 20,354 patients in the Swedish Cancer Register during 1958-88. A second primary cancer was reported in 1605 patients, compared with an expected number of 1109.5 [standardised incidence ratio (SIR) = 1.45, 95% confidence interval (CI) = 1.38-1.52]. The highest risk was found among patients younger than 60 years. The greatest risk was seen during the first year after diagnosis (SIR = 1.91, CI = 1.69-2.14), but even after long-term follow-up--15 years or more--the risk was still significantly elevated (SIR = 1.56, CI = 1.35-1.79). The strongest association was found for a second primary malignant melanoma (men, SIR = 10.0, CI = 8.26-12.00; women, SIR = 8.66, CI = 7.22-10.30) and non-melanoma skin cancer (men, SIR = 3.58, CI = 2.85-4.44; women, SIR = 2.41, CI = 1.71-3.29). The risk of second cancers associated with tissues of neuroectodermal origin was increased, especially tumours of the nervous system (men, SIR = 1.73, CI = 1.10-2.60; women, SIR = 2.03, CI = 1.45-2.78). The SIR of second cancers involving the immune system was also increased. An excess risk of endometrial cancer was seen (SIR = 1.41, CI = 1.03-1.88), but no significant associations existed for cancers of the breast, ovary, testis or other endocrine glands. Among tumours of the digestive tract, only colon cancer in men had a significantly increased SIR (1.33, CI = 1.00-1.74).

Full text

PDF
255

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BENNETT I. L., Jr, FINLAND M., HAMBURGER M., KASS E. H., LEPPER M., WAISBREN B. A. A double-blind study of the effectiveness of cortisol in the management of severe infections. Trans Assoc Am Physicians. 1962;75:198–207. [PubMed] [Google Scholar]
  2. Bergman W., Watson P., de Jong J., Lynch H. T., Fusaro R. M. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990 Jun;61(6):932–936. doi: 10.1038/bjc.1990.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boland S. L., Shaw H. M., Milton G. W. Multiple primary cancers in patients with malignant melanoma. Med J Aust. 1976 Apr 10;1(15):517–519. [PubMed] [Google Scholar]
  4. Evans R. D., Kopf A. W., Lew R. A., Rigel D. S., Bart R. S., Friedman R. J., Rivers J. K. Risk factors for the development of malignant melanoma--I: Review of case-control studies. J Dermatol Surg Oncol. 1988 Apr;14(4):393–408. doi: 10.1111/j.1524-4725.1988.tb03373.x. [DOI] [PubMed] [Google Scholar]
  5. Fisher R. I., Neifeld J. P., Lippman M. E. Oestrogen receptors in human malignant melanoma. Lancet. 1976 Aug 14;2(7981):337–339. doi: 10.1016/s0140-6736(76)92592-7. [DOI] [PubMed] [Google Scholar]
  6. Fraser D. G., Bull J. G., Jr, Dunphy J. E. Malignant melanoma and coexisting malignant neoplasms. Am J Surg. 1971 Aug;122(2):169–174. doi: 10.1016/0002-9610(71)90313-8. [DOI] [PubMed] [Google Scholar]
  7. Greene M. H., Hoover R. N., Fraumeni J. F., Jr Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. J Natl Cancer Inst. 1978 Aug;61(2):337–340. [PubMed] [Google Scholar]
  8. Gutman M., Cnaan A., Inbar M., Shafir R., Chaitchik S., Rozin R. R., Klausner J. M. Are malignant melanoma patients at higher risk for a second cancer? Cancer. 1991 Aug 1;68(3):660–665. doi: 10.1002/1097-0142(19910801)68:3<660::aid-cncr2820680337>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  9. Hersey P., Edwards A., Honeyman M., McCarthy W. H. Low natural-killer-cell activity in familial melanoma patients and their relatives. Br J Cancer. 1979 Jul;40(1):113–122. doi: 10.1038/bjc.1979.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  11. Lindelöf B., Sigurgeirsson B., Wallberg P., Eklund G. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):245–248. doi: 10.1016/0190-9622(91)70189-9. [DOI] [PubMed] [Google Scholar]
  12. Magnus K. Incidence of malignant melanoma of the skin in the five Nordic countries: significance of solar radiation. Int J Cancer. 1977 Oct 15;20(4):477–485. doi: 10.1002/ijc.2910200402. [DOI] [PubMed] [Google Scholar]
  13. Mattsson B., Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305–313. doi: 10.3109/02841868409136026. [DOI] [PubMed] [Google Scholar]
  14. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  15. Osterlind A., Tucker M. A., Stone B. J., Jensen O. M. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer. 1988 Sep 15;42(3):319–324. doi: 10.1002/ijc.2910420303. [DOI] [PubMed] [Google Scholar]
  16. SNELL R. S., BISCHITZ P. G. The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol. 1960 Aug;35:73–82. doi: 10.1038/jid.1960.87. [DOI] [PubMed] [Google Scholar]
  17. Schallreuter K. U., Levenig C., Berger J. Cutaneous malignant melanomas with other coexisting neoplasms: a true association? Dermatology. 1993;186(1):12–17. doi: 10.1159/000247296. [DOI] [PubMed] [Google Scholar]
  18. Schoenberg B. S., Christine B. W. Malignant melanoma associated with breast cancer. South Med J. 1980 Nov;73(11):1493–1497. doi: 10.1097/00007611-198011000-00023. [DOI] [PubMed] [Google Scholar]
  19. Slingluff C. L., Jr, Reintgen D. S., Vollmer R. T., Seigler H. F. Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg. 1990 May;211(5):552–559. doi: 10.1097/00000658-199005000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stedman K. E., Moore G. E., Morgan R. T. Estrogen receptor proteins in diverse human tumors. Arch Surg. 1980 Mar;115(3):244–248. doi: 10.1001/archsurg.1980.01380030004002. [DOI] [PubMed] [Google Scholar]
  21. Thörn M., Adami H. O., Ringborg U., Bergström R., Krusemo U. B. Long-term survival in malignant melanoma with special reference to age and sex as prognostic factors. J Natl Cancer Inst. 1987 Nov;79(5):969–974. [PubMed] [Google Scholar]
  22. Thörn M., Bergström R., Adami H. O., Ringborg U. Trends in the incidence of malignant melanoma in Sweden, by anatomic site, 1960-1984. Am J Epidemiol. 1990 Dec;132(6):1066–1077. doi: 10.1093/oxfordjournals.aje.a115749. [DOI] [PubMed] [Google Scholar]
  23. Travis L. B., Curtis R. E., Boice J. D., Jr, Hankey B. F., Fraumeni J. F., Jr Second cancers following non-Hodgkin's lymphoma. Cancer. 1991 Apr 1;67(7):2002–2009. doi: 10.1002/1097-0142(19910401)67:7<2002::aid-cncr2820670729>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  24. Travis L. B., Curtis R. E., Glimelius B., Holowaty E., Van Leeuwen F. E., Lynch C. F., Adami J., Gospodarowicz M., Wacholder S., Inskip P. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993 Dec 1;85(23):1932–1937. doi: 10.1093/jnci/85.23.1932. [DOI] [PubMed] [Google Scholar]
  25. Travis L. B., Curtis R. E., Hankey B. F., Fraumeni J. F., Jr Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992 Sep 16;84(18):1422–1427. doi: 10.1093/jnci/84.18.1422. [DOI] [PubMed] [Google Scholar]
  26. Tucker M. A., Boice J. D., Jr, Hoffman D. A. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985 Dec;68:161–189. [PubMed] [Google Scholar]
  27. Tucker M. A., Misfeldt D., Coleman C. N., Clark W. H., Jr, Rosenberg S. A. Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med. 1985 Jan;102(1):37–41. doi: 10.7326/0003-4819-102-1-37. [DOI] [PubMed] [Google Scholar]
  28. van Leeuwen F. E., Klokman W. J., Hagenbeek A., Noyon R., van den Belt-Dusebout A. W., van Kerkhoff E. H., van Heerde P., Somers R. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994 Feb;12(2):312–325. doi: 10.1200/JCO.1994.12.2.312. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES